focus -WSS

focus

author：focus 2025-09-29 16:36:19 - browse：94

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： A disappointing year of Humira biosimilars

knowledge

leisure time

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

National panel will explore requiring free Covid tests

New safety details link Apellis eye drug to rare cases of blindness

Medicare Advantage proposed rates disappoint insurers

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Amazon expands telehealth clinic nationwide

Wikipedia

focus

leisure time

Activists slam private health insurers over coverage restrictions

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Cancer drug shortages should be causing more outrage

Micronoma's microbiome cancer diagnostic approach under fire

Virginia high school admissions case could be legal follow

Lawsuit alleges UnitedHealth Group unit illegally denied claims

The cancer drug shortage isn’t new — and neither are the solutions

Private equity deals in Medicare Advantage declines

Wildfire smoke exposes gaps in outdoor worker protections

What we’ve learned from the Aduhelm mess

explore

Trump indictment: Who are the 'co

New safety details link Apellis eye drug to rare cases of blindness

New safety details link Apellis eye drug to rare cases of blindness

Doctors' information doesn't help them choose wisely when sick

New safety details link Apellis eye drug to rare cases of blindness

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

explore

knowledge

leisure time

hotspot